SPYRE THERAPEUTICS, INC.

Analyst Reco. Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Real-time Estimate Cboe BZX Other stock markets 15:19:16 29/04/2024 BST			5-day change	1st Jan Change
34.98 ^USD	+4.23%		+0.50%	+55.48%

04-19	Sector Update: Health Care Stocks Steady Pre-Bell Friday	MT
04-19	Spyre Therapeutics Files Mixed-Securities Shelf Registration for About 33.4 Million Shares	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating	03-26	MT
Wells Fargo Upgrades Spyre Therapeutics to Overweight From Equalweight, Raises Price Target to $35 From $12	03-01	MT
BTIG Initiates Spyre Therapeutics With Buy Rating, Price Target is $32	12-20	MT
Stifel Adjusts Price Target on Spyre Therapeutics to $27 From $23, Keeps Buy Rating	12-18	MT
Jefferies Initiates Spyre Therapeutics at Buy Rating With $31 Price Target	12-11	MT
Wells Fargo Adjusts Price Target on Aeglea BioTherapeutics to $0.50 From $0.35, Maintains Equal-Weight Rating	16/08/23	MT
Stifel Initiates Aeglea BioTherapeutics With Buy Rating, $0.90 Price Target	25/07/23	MT
LifeSci Capital Downgrades Aeglea BioTherapeutics to Market Perform From Outperform	12/04/23	MT
JonesTrading Downgrades Aeglea BioTherapeutics to Hold From Buy	12/04/23	MT
Piper Sandler Lifts Aeglea BioTherapeutics to Overweight From Neutral, Price Target to $1.50 From $1	28/10/22	MT
Wells Fargo Lifts Aeglea BioTherapeutics to Overweight From Equalweight, Price Target to $2 From $1.50	28/10/22	MT
Needham Downgrades Aeglea BioTherapeutics to Hold From Buy	03/06/22	MT
Piper Sandler Downgrades Aeglea BioTherapeutics to Neutral From Overweight, Cuts Price Target to $1 From $4, Shares Dive 46%	02/06/22	MT
HC Wainwright Downgrades Aeglea BioTherapeutics to Neutral From Buy, Cuts Price Target to $1 From $17	02/06/22	MT
Piper Sandler Adjusts Price Target for Aeglea BioTherapeutics to $4 From $7, Maintains Overweight Rating	23/05/22	MT
Piper Sandler Adjusts Aeglea BioTherapeutics' Price Target to $7 From $9, Reiterates Overweight Rating	09/05/22	MT
HC Wainwright Adjusts Price Target on Aeglea BioTherapeutics to $17 From $20, Reiterates Buy Rating	06/05/22	MT
AEGLEA BIOTHERAPEUTICS : HC Wainwright Adjusts Aeglea BioTherapeutics' Price Target to $15 from $17, Keeps Buy Rating	09/11/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer